The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death
C Merkel, G Marchesini, A Fabbri, S Bianco, G Bianchi, E Enzo, D Sacerdoti, M Zoli, A Gatta – 1 October 1996 – There is increasing interest for the use of surrogate end points in the evaluation of treatments in patients with liver disease, but adequate validation is seldom available. This study aimed to describe the different course of galactose elimination capacity in patients with alcoholic cirrhosis who continued to drink or abstained from alcohol consumption during follow‐up, and to validate changes in galactose elimination as a surrogate end point for death from liver‐related causes.